AR063550A2 - Utilizacion de un derivado de pirazol para la preparcion de medicamentos utiles para la prevencion y eltratamiento de la displidemias y de las enefermedades asociadas a las dislipidemias y/o a la obesidad - Google Patents

Utilizacion de un derivado de pirazol para la preparcion de medicamentos utiles para la prevencion y eltratamiento de la displidemias y de las enefermedades asociadas a las dislipidemias y/o a la obesidad

Info

Publication number
AR063550A2
AR063550A2 ARP070104904A ARP070104904A AR063550A2 AR 063550 A2 AR063550 A2 AR 063550A2 AR P070104904 A ARP070104904 A AR P070104904A AR P070104904 A ARP070104904 A AR P070104904A AR 063550 A2 AR063550 A2 AR 063550A2
Authority
AR
Argentina
Prior art keywords
obesity
prevention
preparation
displidemies
dislipidemies
Prior art date
Application number
ARP070104904A
Other languages
English (en)
Inventor
Hassan Massoud Heshmati
Mohammed Bensaid
Michele Arnone
Jean-Marc Herbert
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34426973&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR063550(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from FR0312553A external-priority patent/FR2861300B1/fr
Priority claimed from FR0314763A external-priority patent/FR2861301B1/fr
Priority claimed from FR0401193A external-priority patent/FR2861302A1/fr
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of AR063550A2 publication Critical patent/AR063550A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

Utilizacion de un compuesto antagonista de los receptores de cannabinoides CB1, derivado de pirazol, solo o asociado con otro principio activo, para la preparacion de medicamentos utiles para la prevencion y el tratamiento de las dislipidemias y de las enfermedades asociadas a las dislipidemias y/o a la obesidad, tales como el síndrome metabolico, los riesgos cardiovasculares y las enfermedades hepáticas.
ARP070104904A 2003-10-24 2007-11-05 Utilizacion de un derivado de pirazol para la preparcion de medicamentos utiles para la prevencion y eltratamiento de la displidemias y de las enefermedades asociadas a las dislipidemias y/o a la obesidad AR063550A2 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR0312553A FR2861300B1 (fr) 2003-10-24 2003-10-24 Utilisation d'un derive du pyrazole, pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique
FR0314763A FR2861301B1 (fr) 2003-10-24 2003-12-15 Utilisation du derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique.
FR0401193A FR2861302A1 (fr) 2003-10-24 2004-02-05 Utilisation d'un derive du pyrazole, pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique.
FR0403252A FR2861303A1 (fr) 2003-10-24 2004-03-26 Utilisation d'un derive de pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique

Publications (1)

Publication Number Publication Date
AR063550A2 true AR063550A2 (es) 2009-01-28

Family

ID=34426973

Family Applications (3)

Application Number Title Priority Date Filing Date
ARP040103811A AR047764A1 (es) 2003-10-24 2004-10-21 Utilizacion de un derivado de pirazol para la preparacion de medicamentos utiles para la prevencion y el tratamiento de las dislipidemias y de las enfermedades asociadas a las dislipidemias y/o a la obesidad
ARP070104905A AR063551A2 (es) 2003-10-24 2007-11-05 Utilizacion de un derivado de pirazol para la preparcion de medicamentos utiles para la prevencion y el tratamiento de las disciplinas y de las enfermedades asociadas a las dislipidemias y/o a la obesidad
ARP070104904A AR063550A2 (es) 2003-10-24 2007-11-05 Utilizacion de un derivado de pirazol para la preparcion de medicamentos utiles para la prevencion y eltratamiento de la displidemias y de las enefermedades asociadas a las dislipidemias y/o a la obesidad

Family Applications Before (2)

Application Number Title Priority Date Filing Date
ARP040103811A AR047764A1 (es) 2003-10-24 2004-10-21 Utilizacion de un derivado de pirazol para la preparacion de medicamentos utiles para la prevencion y el tratamiento de las dislipidemias y de las enfermedades asociadas a las dislipidemias y/o a la obesidad
ARP070104905A AR063551A2 (es) 2003-10-24 2007-11-05 Utilizacion de un derivado de pirazol para la preparcion de medicamentos utiles para la prevencion y el tratamiento de las disciplinas y de las enfermedades asociadas a las dislipidemias y/o a la obesidad

Country Status (18)

Country Link
US (2) US20070072907A1 (es)
EP (1) EP1680117A2 (es)
JP (1) JP2007509113A (es)
KR (1) KR20060100443A (es)
AR (3) AR047764A1 (es)
AU (1) AU2004289078A1 (es)
BR (1) BRPI0415538A (es)
CA (1) CA2543582A1 (es)
FR (1) FR2861303A1 (es)
IL (1) IL175103A0 (es)
MA (1) MA28105A1 (es)
ME (1) MEP10608A (es)
NZ (1) NZ547375A (es)
RS (1) RS20060344A (es)
RU (1) RU2357731C2 (es)
SG (1) SG149078A1 (es)
TW (1) TWI286935B (es)
WO (1) WO2005046689A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1574211A1 (en) * 2004-03-09 2005-09-14 Inserm Use of antagonists of the CB1 receptor for the manufacture of a composition useful for the treatment of hepatic diseases
EP1745782A1 (en) * 2005-07-15 2007-01-24 Laboratorios Del Dr. Esteve, S.A. Use of substitued pyrazoline compounds for the preparation of medicaments for the treatment of metabolic syndrome
ES2326857B1 (es) * 2005-07-15 2010-05-11 Laboratorios Del Dr. Esteve, S.A. Uso de compuestos de pirazolina sustituidos para el tratamiento de los parametros lipidicos del sindrome metabolico.
WO2007009698A1 (en) * 2005-07-15 2007-01-25 Laboratorios Del Dr. Esteve, S.A Combination of pyrazoline type cannabinoid receptor antagonist and statin
ES2325722B1 (es) * 2005-07-15 2010-04-19 Laboratorios Del Dr.Esteve, S.A. Uso de compuestos de pirazolina sustituidos para la preparacion de medicamentos para el tratamiento del sindrome metabolico.
EP1745781A1 (en) * 2005-07-15 2007-01-24 Laboratorios Del Dr. Esteve, S.A. Combination of pyrazoline type cannabinoid receptor antagonist and statin
EP1946779A1 (en) * 2007-01-16 2008-07-23 Laboratorios del Dr. Esteve S.A. Combination of substituted pyrazolines and agent for treating dyslipidemia
EP1985295A1 (en) 2007-04-04 2008-10-29 Institut National De La Sante Et De La Recherche Medicale (Inserm) Selective inhibitors of CB2 receptor expression and/or activity for the treatment of obesity and obesity-related disorders
KR101057485B1 (ko) 2008-08-04 2011-08-17 서울대학교산학협력단 1,2-디티올티온 유도체를 함유하는 엘엑스알-알파 과다발현으로 인한 질병의 예방 및 치료용 약학 조성물
WO2010079241A1 (es) 2009-01-12 2010-07-15 Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion Uso de antagonistas y/o agonistas inversos de los receptores cb1 para la preparación de medicamentos que incrementen la excitabilidad de las motoneuronas
ES2349838B1 (es) * 2009-05-04 2011-11-15 Instituto Mediterraneo Para El Avance De La Biotecnologia Y La Investigacion Sanitaria (Fundacion Im Derivados de pirazol bivalentes como inhibidores de ingesta
RU2568896C2 (ru) * 2013-07-31 2015-11-20 Общество С Ограниченной Ответственностью "Научно-Производственная Фирма "Материа Медика Холдинг" Лекарственное средство на основе вещества, влияющего на эндоканнабиноидную систему
WO2018064654A1 (en) * 2016-10-01 2018-04-05 James Smeeding Pharmaceutical compositions comprising a statin and a cannabinoid and uses thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2758723B1 (fr) * 1997-01-28 1999-04-23 Sanofi Sa Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
FR2789079B3 (fr) * 1999-02-01 2001-03-02 Sanofi Synthelabo Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant
FR2799124B1 (fr) * 1999-10-01 2004-08-13 Sanofi Synthelabo Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
US20020091114A1 (en) * 2000-10-04 2002-07-11 Odile Piot-Grosjean Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity
FR2814678B1 (fr) * 2000-10-04 2002-12-20 Aventis Pharma Sa Association d'un antagoniste du recepteur cb1 et de sibutramine, les compositions pharmaceutiques les contenant et leur utilisation pour la traitement de l'obesite
HUP0401567A3 (en) * 2001-09-21 2005-06-28 Solvay Pharm Bv Novel 4,5-dyhydro-1h-pyrazole derivatives having cb1-antagonistic activity, their use and pharmaceutical compositions containing them
US6864268B2 (en) * 2002-02-27 2005-03-08 Pfizer Inc. β3 adrenergic receptor agonists
DE60334787D1 (de) * 2002-03-12 2010-12-16 Merck Sharp & Dohme Substituierte amide
WO2003087037A1 (en) * 2002-04-05 2003-10-23 Merck & Co., Inc. Substituted aryl amides
KR101120337B1 (ko) * 2002-07-09 2012-02-29 브리스톨-마이어스 스큅 컴퍼니 항당뇨제 및 항비만제로서 유용한 치환된 헤테로시클릭유도체 및 방법
US20050288213A1 (en) * 2002-07-18 2005-12-29 Macneil Douglas J Combination therapy for the treatment of obesity
AU2003257145B2 (en) * 2002-08-02 2008-11-13 Merck Sharp & Dohme Corp. Substituted furo (2,3-b) pyridine derivatives
US20050101542A1 (en) * 2002-08-20 2005-05-12 Regents Of The University Of California Combination therapy for controlling appetites
US6869966B2 (en) * 2002-09-30 2005-03-22 Banyu Pharmaceutical Co., Ltd. N-substituted-2-oxodihydropyridine derivatives
US20040214804A1 (en) * 2003-04-25 2004-10-28 Pharmacia Corporation Combination of an aldosterone receptor antagonist and an anti-obesity agent
US20070099884A1 (en) * 2003-06-06 2007-05-03 Erondu Ngozi E Combination therapy for the treatment of diabetes
EP1635813A4 (en) * 2003-06-06 2009-07-01 Merck & Co Inc COMBINATION THERAPY FOR THE TREATMENT OF DYSLIPIDEMIA
WO2004110368A2 (en) * 2003-06-06 2004-12-23 Merck & Co., Inc. Combination therapy for the treatment of hypertension
RU2006110545A (ru) * 2003-09-02 2007-10-10 Зольвай Фармасьютикалз Гмбх (De) Новое медицинское применение избирательных антагонистов св1-рецептора
US7371759B2 (en) * 2003-09-25 2008-05-13 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
EP1680116A1 (en) * 2003-10-24 2006-07-19 Solvay Pharmaceuticals GmbH Combination treatment of obesity involving selective cb1-antagonists and lipase inhibitors
EP1574211A1 (en) * 2004-03-09 2005-09-14 Inserm Use of antagonists of the CB1 receptor for the manufacture of a composition useful for the treatment of hepatic diseases
WO2005094305A2 (en) * 2004-03-31 2005-10-13 Neurogen Corporation Combination therapy for weight management
US20050281868A1 (en) * 2004-06-21 2005-12-22 Fairfield Clinical Trials, Llc Transdermal delivery system for statin combination therapy

Also Published As

Publication number Publication date
MEP10608A (en) 2010-06-10
KR20060100443A (ko) 2006-09-20
MA28105A1 (fr) 2006-08-01
US20090215755A1 (en) 2009-08-27
RS20060344A (en) 2008-08-07
WO2005046689A2 (fr) 2005-05-26
AR063551A2 (es) 2009-01-28
JP2007509113A (ja) 2007-04-12
US20070072907A1 (en) 2007-03-29
IL175103A0 (en) 2008-04-13
AU2004289078A1 (en) 2005-05-26
TWI286935B (en) 2007-09-21
EP1680117A2 (fr) 2006-07-19
BRPI0415538A (pt) 2006-12-26
RU2006117790A (ru) 2007-12-10
CA2543582A1 (fr) 2005-05-26
RU2357731C2 (ru) 2009-06-10
SG149078A1 (en) 2009-01-29
AR047764A1 (es) 2006-02-22
WO2005046689A3 (fr) 2005-10-13
FR2861303A1 (fr) 2005-04-29
NZ547375A (en) 2009-10-30
TW200526216A (en) 2005-08-16

Similar Documents

Publication Publication Date Title
AR063550A2 (es) Utilizacion de un derivado de pirazol para la preparcion de medicamentos utiles para la prevencion y eltratamiento de la displidemias y de las enefermedades asociadas a las dislipidemias y/o a la obesidad
MY149622A (en) Pyrazoles as 11-beta-hsd-1
MX2007012212A (es) 1h-pirazol 4-carboxilamidas, su preparacion y su uso como 11-beta-hidroxiesteroide deshidrogenasa.
MX2009006339A (es) Compuestos y composiciones como inhibidores de actividad de receptor 1 de cannabinoide.
TW200630096A (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
NO20090593L (no) Modulatorer av farmakokinetikkegenskaper til terapeutika
TN2011000172A1 (en) Therapeutic antiviral peptides
ATE442349T1 (de) Diacylglycerol-acyltransferase-hemmer
NO20064041L (no) Substituerte pyrazolin sammensetninger, deres fremstilling og anvendelse som medikamenter
BRPI0520669A2 (pt) dosagem farmacêutica que reduz o efeito do alimento encontrado para administração de atorvastatina
ECSP088852A (es) Azolopirimidinas como inhibidores de la actividad canabinoidea 1
NO20083821L (no) Polymerpreparater av CETP-inhibitorer
GT200700096A (es) Compuestos de pirazolina
WO2008043544A8 (en) Sulfonamide substituted pyrazoline compounds, their preparation and use as cb1 modulators
NO341679B1 (no) Substituerte pyridylamidforbindelser, fremstilling av slike og farmasøytiske sammensetninger inneholdende slike, samt anvendelse som modulatorer av histamin H3-reseptoren
TW200738699A (en) 4-Substituted pyrazoline compounds, their preparation and use as medicaments
MX2010001574A (es) Ligandos del receptor cannabinoide.
DE602007014036D1 (de) 12-aryl-prostaglandin-analoga
EA201070689A1 (ru) Композиция для личного ухода
WO2008008700A3 (en) Substituted cyclopentane derivatives as therapeutic agents
BRPI0716643A2 (pt) amidas terapêuticas e compostos relacionados
BRPI0509014A (pt) comprimidos desintegráveis que compreendem licarbazepina
UY28576A1 (es) Utilización de un derivado de pirazol para la preparación de medicamentos utiles para la prevención y el tratamiento de las dislipidemias y de las enfermedades asociadas a las dislipidemias y/o a la obesidad
DOP2004001017A (es) Utilizacion de un derivado de pirazol para la preparacion y el tratamiento de las dislipidemias y de las enfermedades asociadas a las dislipidemias y/o a la obesidad
NO20062369L (no) Anvendelse av et pyrazoldedvat for fiemstilling av medikamenter for a hindre og behandle dyslipideml og sykdommer assosiert med dyslipidemi og/eller fedme

Legal Events

Date Code Title Description
FB Suspension of granting procedure